# Clinical Trials Data KRAS - Document 35

# Midostaurin (PKC412) for Locally Advanced Rectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01282502

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Adenocarcinoma of the rectum\n\* T3/4 or N+ disease\n\* Life expectancy \\> 3 months\n\* Normal organ and marrow function\n\nExclusion Criteria:\n\n\* Metastatic disease\n\* Pregnant or breastfeeding\n\* Prior radiotherapy\n\* Receiving other investigational agents\n\* History of inflammatory bowel disease\n\* Active scleroderma or CREST syndrome\n\* Uncontrolled intercurrent illness\n\* History of a different malignancy unless disease free for at least 5 years\n\* HIV or active viral hepatitis\n\* Impaired cardiac function",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention KRAS mutation status as either an inclusion or exclusion criterion. Therefore, having a KRAS mutation \*does not automatically disqualify\* a patient. They could still be eligible if they meet all other inclusion criteria and none of the exclusion criteria.